HCA
HCA HealthcarePrevious close
473.19
Change
−4.89 / −1.02%
P/E (TTM) ?
15.0
Market Cap
$104B
1M
+10.88%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.1M / 1.5M
0.77× average
Latest earnings analysisFY2026 Q2Reported 2026-07-14
HCA Q2 2026: revenue up 8.7%, EPS beat, but profit guidance cut
HCA's headline growth is real but flattered: revenue rose 8.7% to $20.230 billion, with $1.372 billion of Florida directed-payment catch-up baked in. Adjusted EPS of $7.59 inched past the $7.5425 consensus, helped by a shrinking share count. Management still cut full-year profit guidance, citing uninsured volume from lapsed exchange coverage. Read the quarter as volume-driven but payer-mix pressured: Neutral.
Read the full analysis →Revenue$20.23BYoY +8.70%
EPS (non-GAAP)$7.59Beatest. $7.54
Next-quarter revenue guidance$78.25B ±1.6%YoY +286.80%
Next-day move+4.19%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-14 | $20.2B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-24 | $19.1B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-27 | $75.6B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-24 | $19.2B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-25 | $18.6B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-01 | $18.3B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 41 of its 5-year rangeMid-range
5-year range 12.4 – 19.0 · Median 15.8
Last 4 quarters: $9.2B in buybacks + $681M in dividends, 9.50% of market cap combined
P/E (TTM)
15.0
P/B
—
P/S
1.3
Dividend Yield
0.95%
Earnings Reaction
Over the last 6 reports, the stock moved ±3.0% on average on the first trading day after, rising 5 times
Most recent +4.19%
Volatility & Correlation
1-year beta -0.01 · Correlation with S&P 500 0.00Low beta
Annualized volatility 32% vs. 12% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 19.85 | +3.6% | — | 1.58 | 7.27 |
| FY2026 Q2 | 20.23 | +8.7% | — | 1.70 | 7.62 |
| FY2026 Q1 | 19.11 | +4.3% | — | 1.62 | 7.15 |
| FY2025 Q4 | 19.51 | +6.7% | — | 1.88 | 8.09 |
| FY2025 Q3 | 19.16 | +9.6% | — | 1.64 | 6.96 |
| FY2025 Q2 | 18.61 | +6.4% | — | 1.65 | 6.83 |
| FY2025 Q1 | 18.32 | +5.7% | — | 1.61 | 6.45 |
| FY2024 Q4 | 18.29 | +5.7% | — | 1.44 | 5.66 |
| FY2024 Q3 | 17.49 | +7.9% | — | 1.27 | 4.88 |
| FY2024 Q2 | 17.49 | +10.3% | — | 1.46 | 5.53 |
| FY2024 Q1 | 17.34 | +11.2% | — | 1.59 | 5.93 |
| FY2023 Q4 | 17.30 | +11.7% | — | 1.61 | 5.92 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| HCA | 15.0 | +3.6% | — | +10.88% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |